<DOC>
	<DOCNO>NCT02006758</DOCNO>
	<brief_summary>The purpose observational study evaluate safety performance EnligHTN™ Renal Denervation System treatment patient uncontrolled hypertension clinical routine practice .</brief_summary>
	<brief_title>Observational Study EnligHTN Renal Denervation System Europe</brief_title>
	<detailed_description>The EnligHTN European Observational study design collect data , critical benefit therapy , within clinical routine setting .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<criteria>Subject plan undergo renal denervation procedure treatment hypertension Subject ≥18 year age time consent Subject must able willing provide write informed consent Subject must able willing comply require followup schedule Subject office SBP ≥ 140 mmHg Subject establish hypertension ( diagnose ≥12 month prior baseline ) guideline base drug regimen stable ( ≥ 14 day ) fully tolerate dose consist ≥3 antihypertensive medication ( include 1 diuretic ) Subject know significant renovascular abnormality renal artery stenosis &gt; 30 % Subject undergone prior renal angioplasty , renal denervation , indwell renal stent , and/or abdominal aortic stent graft Subject history hemodynamically significant valvular heart disease Subject blood clot abnormality Subject life expectancy &lt; 12 month , determine Study Investigator Subject participate another clinical study potential impact his/her hypertension management ( pharmaceutical/ device/ homeopathic ) Subject pregnant , nursing , childbearing potential use adequate contraceptive method Subject active systemic infection Subject know renal artery diameter ( ) &lt; 4 mm Subject estimate GFR &lt; 45 mL/min per 1.73 m2 use Modification Diet Renal Disease ( MDRD ) formula Subject renal transplant await renal transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>